{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-367001","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2021-12-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.427615+00:00","generated_at":"2026-06-27T22:20:14.504086+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Reneo Pharma CBO Wendy Johnson to depart Dec 31, enters consulting agreement","bullets":["Wendy Johnson will cease as CBO on Dec 31, 2021; will serve as consultant for 18 months.","Severance of $100k contingent on release of claims; continues base salary of $365k/yr until separation.","Equity awards continue to vest during consulting period; full acceleration if Company terminates without cause before June 30, 2023.","Cash consulting fee of $10k/month plus hourly rate for over 32 hours/month."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-367001","json":"https://secwatch.observer/filing/0001193125-21-367001.json","markdown":"https://secwatch.observer/filing/0001193125-21-367001.md","text":"https://secwatch.observer/filing/0001193125-21-367001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312521367001/0001193125-21-367001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312521367001/d237276d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T22:20:14.504086+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b10826ac6","claim":"Wendy Johnson resigned as Chief Business Officer at OnKure Therapeutics, Inc..","evidence_excerpt":"On December 23, 2021, Reneo Pharmaceuticals, Inc. (the “Company”) entered into a Transition, Separation and Consulting Agreement (the “Agreement”) with Wendy Johnson, in connection with her previously announced resignation from the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312521367001/0001193125-21-367001-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Business Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}